Any questions? Contact us+49 761-389 49-0

Seraseq® ctDNA MRD Panel Mix

Seraseq® ctDNA MRD Panel Mix

Seraseq® ctDNA MRD Panel Mix

#0710-2146 LGC SeraCare has developed a novel ctDNA MRD mutation mix panel designed to support the development, validation and clinical deployment of ctDNA-based patient-derived MRD monitoring NGS assays.
€1,974.00 *

Prices plus VAT plus shipping costs

Delivery time 7 Workdays

Size: 4 x 20 μl (10ng/μl)
  • 0710-2146
MRD monitoring typically involves measuring signs of a cancer in order to determine if it is... more
MRD monitoring typically involves measuring signs of a cancer in order to determine if it is disappearing (progression) or returning (relapse). Typically, this can be facilitated by use of less invasive techniques such as liquid biopsy (ctDNA), to monitor cancer-specific somatic variants. A patient-derived approach to the application of ctDNA-based MRD monitoring starts with a tumor profiling analysis to identify clinically relevant tumor variants that constitute the patient’s genomic profile. Following this, a targeted panel/assay containing a subset of the gene variants can be designed for disease monitoring by detecting presence or absence of circulating tumor (ct)DNA variants in the patient’s blood sample. These patient-derived MRD analyses represent a paradigm shift in disease monitoring, and have been adopted by leading liquid biopsy NGS vendors such as Natera’s Signatera® platform and Archer/Invitae’s Personalized Cancer Monitoring (PCM) assay.

For additional information about the product, please visit the manufacturer's website.
PROPERTIES
storage temperature: -20 °C
shipping method: dry ice
regulatory status: RUO
ONCOaccuPanel™ ONCOaccuPanel™
Preis auf Anfrage
BRCAaccuTest™ PLUS BRCAaccuTest™ PLUS
Preis auf Anfrage
SOLIDaccuTest™ RNA SOLIDaccuTest™ RNA
Preis auf Anfrage
HEMEaccuTest™ RNA HEMEaccuTest™ RNA
Preis auf Anfrage
HEMEaccuTest™ DNA HEMEaccuTest™ DNA
Preis auf Anfrage
Top-Seller
FLT3 ITD MRD Assay FLT3 ITD MRD Assay
Preis auf Anfrage
Viewed